Did Krug & Høeg show Pfizer vaccine-associated myocarditis-pericarditis in adolescents? Yes, alarmingly so! Stratified Risk-Benefit Analysis showed one dose in young males had more risk than benefit
SOURCE:
https://onlinelibrary.wiley.com/doi/10.1111/eci.13759
Evidence indicates that male patients ages 12–17 years have an elevated risk of mRNA vaccination-associated myo/pericarditis. ‘A risk-benefit analysis of first and second doses of mRNA vaccination in adolescent boys by health status and history of SARS-CoV-2 infection has not been performed.’
‘Researchers reported that ‘cases of myo/pericarditis (n = 253) included 129 after dose 1 and 124 after dose 2; 86.9% were hospitalized.
Incidence per million after dose two in male patients aged 12–15 and 16–17 was 162.2 and 93.0, respectively. Weighing post-vaccination myo/pericarditis against COVID-19 hospitalization during delta, our risk-benefit analysis suggests that among 12–17-year-olds, two-dose vaccination was uniformly favourable only in nonimmune girls with a comorbidity. In boys with prior infection and no comorbidities, even one dose carried more risk than benefit according to international estimates. In the setting of omicron, one dose may be protective in nonimmune children, but dose two does not appear to confer additional benefit at a population level.’
Go to Dr Alexancer on Substack
Author: Dr. Paul Alexander
